CASTELLI, MARIA PAOLA
 Distribuzione geografica
Continente #
EU - Europa 132.868
NA - Nord America 6.876
AS - Asia 2.884
SA - Sud America 407
AF - Africa 79
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 7
Totale 143.134
Nazione #
IT - Italia 129.310
US - Stati Uniti d'America 6.784
NL - Olanda 1.894
SG - Singapore 1.188
CN - Cina 976
SE - Svezia 403
UA - Ucraina 376
BR - Brasile 306
VN - Vietnam 236
DE - Germania 218
GB - Regno Unito 183
FI - Finlandia 168
FR - Francia 137
HK - Hong Kong 104
IN - India 88
CA - Canada 67
KR - Corea 57
AR - Argentina 38
JP - Giappone 30
PL - Polonia 30
BD - Bangladesh 29
RU - Federazione Russa 28
IQ - Iraq 23
AT - Austria 20
BE - Belgio 20
ZA - Sudafrica 20
ID - Indonesia 19
TR - Turchia 18
MA - Marocco 17
UZ - Uzbekistan 16
ES - Italia 15
CZ - Repubblica Ceca 14
MX - Messico 14
PH - Filippine 14
SA - Arabia Saudita 14
CL - Cile 13
CO - Colombia 12
VE - Venezuela 12
AU - Australia 10
EC - Ecuador 10
IE - Irlanda 10
TN - Tunisia 10
IL - Israele 9
KE - Kenya 9
PK - Pakistan 9
EG - Egitto 7
MY - Malesia 7
PE - Perù 7
EU - Europa 6
IR - Iran 5
JO - Giordania 5
PY - Paraguay 5
TW - Taiwan 5
AE - Emirati Arabi Uniti 4
CH - Svizzera 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
EE - Estonia 4
ET - Etiopia 4
NO - Norvegia 4
RO - Romania 4
RS - Serbia 4
SN - Senegal 4
AZ - Azerbaigian 3
CR - Costa Rica 3
GE - Georgia 3
GR - Grecia 3
LV - Lettonia 3
NP - Nepal 3
NZ - Nuova Zelanda 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
AM - Armenia 2
BB - Barbados 2
BO - Bolivia 2
DZ - Algeria 2
HR - Croazia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
LT - Lituania 2
MU - Mauritius 2
NG - Nigeria 2
NI - Nicaragua 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
GF - Guiana Francese 1
GH - Ghana 1
IS - Islanda 1
KW - Kuwait 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
SR - Suriname 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 143.134
Città #
Cagliari 126.315
Uta 2.670
Amsterdam 1.868
Fairfield 612
Singapore 595
Ashburn 576
Dallas 549
Woodbridge 481
Chandler 415
Houston 409
San Jose 394
Boardman 273
Ann Arbor 269
Seattle 235
Wilmington 232
Nyköping 231
Jacksonville 204
Cambridge 202
Beijing 179
Dearborn 136
Los Angeles 105
The Dalles 102
Helsinki 101
Santa Clara 98
Hong Kong 94
Shanghai 86
New York 85
Hefei 82
Ho Chi Minh City 74
Lauterbourg 71
Nanjing 63
Boston 62
Munich 62
Council Bluffs 58
Seoul 57
Hanoi 51
Buffalo 41
San Diego 35
Nanchang 31
Dong Ket 29
Frankfurt am Main 29
Orem 27
Hebei 25
Brooklyn 23
Milan 23
Shenyang 23
Washington 23
Chicago 22
London 22
Mountain View 22
Redwood City 22
Tianjin 22
Tokyo 22
Guangzhou 20
Toronto 19
Warsaw 19
Changsha 18
Verona 18
Sassari 17
São Paulo 17
Brussels 16
Chennai 16
Jiaxing 16
Atlanta 15
Jinan 15
Norwalk 15
Phoenix 15
Redondo Beach 15
Rome 15
Montreal 14
Nuremberg 14
Stockholm 14
Tashkent 14
Johannesburg 13
Vienna 13
Falls Church 12
Denver 11
Haiphong 11
Hangzhou 11
Wuhan 11
Baghdad 10
Auburn Hills 9
Casablanca 9
Dhaka 9
Dublin 9
San Francisco 9
Orange 8
Paris 8
Pittsburgh 8
Victoria 8
Brasília 7
Brno 7
Buenos Aires 7
Mumbai 7
New Delhi 7
Piscataway 7
Pune 7
Rio de Janeiro 7
Zhengzhou 7
Bogotá 6
Totale 139.097
Nome #
α2A adrenergic receptors highly expressed in mesoprefrontal dopamine neurons 5.812
Reversible disruption of pre-pulse inhibition in hypomorphic-inducible and reversible CB1-/- mice 5.217
PPARα regulates cholinergic-driven activity of midbrain dopamine neurons via a novel mechanism involving α7 nicotinic acetylcholine receptors. 4.627
Enhanced endocannabinoid-mediated modulation of rostromedial tegmental nucleus drive onto dopamine neurons in sardinian alcohol-preferring rats 4.168
Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135 4.156
Δ9-Tetrahydrocannabinol prevents methamphetamine-induced neurotoxicity 3.898
Regional distribution of 5α-reductase type 2 in the adult rat brain: An immunohistochemical analysis 3.529
Male and Female Rats Differ in Brain Cannabinoid CB1 Receptor Density and Function and in Behavioural Traits Predisposing To Drug Addiction: Effect of Ovarian Hormones. 3.229
The agression and behavioral abnormalities associated with monoamine oxidase A deficiency are rescued by acute inhibition of serotonin reuptake. 3.175
Limited access to a high fat diet alters endocannabinoid tone in female rats 3.089
The Role of the Endocannabinoid System in Eating Disorders: Neurochemical and Behavioural Preclinical Evidence. 2.959
Cannabinoid CB1 receptors in the paraventricular nucleus and central control of penilemerection: immunohistochemistry,autoradiography and behavvioral studies 2.780
Inhibition of steroid 5-alpha reductase reduces marble-burying responses in mice 2.692
Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent 2.662
NMDARs mediate the role of monoamine oxidase A in pathological aggression 2.610
Impaired brain endocannabinoid tone in the activity-based model of anorexia nervosa 2.590
Effects of drugs of abuse on putative rostromedial tegmental neurons, inhibitory afferents to midbrain dopamine cells 2.589
Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a G alpha(i/o) protein inhibitor 2.552
Suppressing effect of saikosaponin A, an active ingredient of Bupleurum falcatum, on chocolate self-administration and reinstatement of chocolate seeking in rats 2.512
In vitro and in vivo pharmacological characterization of SSD114, a novel GABAB positive allosteric modulator 2.465
The new compound GET73, N-[(4-trifluoromethyl)benzyl]4-methoxybutyramide, regulates hippocampal aminoacidergic transmission possibly via an allosteric modulation of mGlu5 receptor. Behavioural evidence of its "anti-alcohol" and anxiolytic properties. 2.406
Methamphetamine induces long-term alterations in reactivity to environmental stimuli: correlation with dopaminergic and serotoninergic toxicity 2.382
The cannabinoid receptor antagonist SR-141716A induces penile erection in male rats: Involvement of paraventricular glutamic acid and nitric oxide 2.342
In vitro functional characterization of GET73 as possible negative allosteric modulator of metabotropic glutamate receptor 5 2.256
Activation of GABA(B) receptors reverses spontaneous gating deficits in juvenile DBA/2J mice 2.151
Characterization of COR627 and COR628, Two Novel Positive Allosteric Modulators of the GABAB Receptor. 2.087
Methamphetamine neurotoxicity increases brain expression and alters behavioral functions of CB(1) cannabinoid receptors 2.074
NMDA receptors mediate the role of monoamine oxidase A in pathological aggression 2.058
null 2.010
Cannabis and the Use of Amphetamine-Like Substances 1.936
Distribution and localization of the GABAB receptor 1.934
6-Hydroxydopamine lesion in the ventral tegmental area fails to reduce extracellular dopamine in the cerebral cortex 1.932
Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe 1.913
Persistent increase in CB1 receptor and amnestic effect of cannabinoid by methamphetamine 1.896
null 1.888
Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2 1.817
(-) S amisulpride binds with high affinity to cloned dopamine D3 and D2 receptors 1.816
Cannabinoid CB1 receptors in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioural studies 1.796
Anti-Alcohol and Anxiolytic Properties of a New Chemical Entity, GET73. 1.706
Localization of steroid 5α-reductase type 2 isozyme in the adult rat brain 1.692
Differential G-protein coupling to GABAB receptor in limbic areas of alcohol-preferring and -nonpreferring rats 1.684
A review of pharmacology of NCS-382, a putative antagonist of gamma-hydroxybutyric acid (GHB) receptor 1.538
Midbrain 6-OHDA lesion fails to reduce extracellular dopamine in cerebral cortex. 1.472
Structure optimization of positive allosteric modulators of GABAB receptors led to the unexpected discovery of antagonists/potential negative allosteric modulators 1.393
Adolescent exposure to nicotine and/or the cannabinoid agonist CP 55,940 induces gender-dependent long lasting memory impairments and changes in brain nicotinic and CB1 cannabinoid receptors 1.382
Sex and gender differences in the effects of novel psychoactive substances 1.368
Changes induced by acute toxic dose (ATD) of methanphetamine (METH) on cannabinoid CB1 receptors: An immunocytochemistry study 1.251
Methamphetamine-induced damages of serotoninergic and dopaminergic terminals are not paralleled by overt mnemonic and pre-attentional alterations 1.139
COR758, a negative allosteric modulator of GABAB receptors 1.136
The GABAB receptor positive allosteric modulator COR659: in vitro metabolism, in vivo pharmacokinetics in rats, synthesis and pharmacological characterization of metabolically protected derivatives 1.120
Multi-faceted aspects of gamma-hydroxybutyric acid: a neurotransmitter, therapeutic agent and drug of abuse 1.044
Human neuronal cell lines as an in vitro toxicological tool for the evaluation of novel psychoactive substances 1.041
Repeated exposure to JWH-018 induces adaptive changes in the mesolimbic and mesocortical dopamine pathways, glial cells alteration and behavioural correlates 1.025
Predisposition to alcohol drinking and alcohol consumption alter expression of calcitonin gene-related peptide, neuropeptide Y, and microglia in bed nucleus of stria terminalis in a subnucleus-specific manner 994
Chronic morphine and naltrexone fail to modify µ-opioid receptor mRNA levels in the rat brain 940
Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists 860
Up-regulation of GABA(B) receptors by chronic administration of the GABA(B) receptor antagonist SCH 50,911 832
Distribution of GABA B receptor mRNAs in the rat brain and peripheral organs 759
Stereoselectivity of NCS-382 binding to gamma-hydroxybutyrate (GHB) receptor in the rat brain 756
Pharmacological characterization of novel synthetic opioids: Isotonitazene, metonitazene, and piperidylthiambutene as potent μ-opioid receptor agonists 706
Selective gamma-hydroxybutyric acid receptor ligands increase extracellular glutamate in hippocampus, but fail to activate G protein and to produce the sedative/hypnotic effect of gamma-hydroxybutyric acid 704
Adolescent self-administration of the synthetic cannabinoid receptor agonist JWH-018 induces neurobiological and behavioral alterations in adult male mice 692
Continuous subcutaneous insulin infusion (CSII) in pregnant diabetic patients 645
Reconstitution of the human 5-HT(1D) receptor-G-protein coupling: evidence for constitutive activity and multiple receptor conformations 643
Thyroid transcription factor 1 activates the promoter of the tyrothropin receptor gene 631
Central effects of 1,4-butanediol are mediated by GABAB receptors via its conversion into gamma-hydroxybutyric acid 623
Quantitative autoradiographic distribution of gamma-hydroxybutyric acid binding sites in human and monkey brain 622
Immune and glial cell alterations in the rat brain after repeated exposure to the synthetic cannabinoid JWH-018 621
3‐[3‐(Phenalkylamino)cyclohexyl]phenols: Synthesis, biological activity, and in silico investigation of a naltrexone‐derived novel class of MOR‐antagonists 620
CATHEPSIN-G INDUCED RELEASE OF PAI-1 IN THE CULTURE-MEDIUM OF ENDOTHELIAL-CELLS - A NEW THROMBOGENIC ROLE FOR POLYMORPHONUCLEAR LEUKOCYTES 589
Synthesis and pharmacological characterization of 2-(acylamino)thiophene derivatives as metabolically stable, orally effective, positive allosteric modulators of the GABAB receptor 571
Molecular pharmacology of the Beta-adrenergic receptor on THP-1 cells 570
Maternal immune activation impairs endocannabinoid signaling in the mesolimbic system of adolescent male offspring 561
Recombinant cytokines IL-2, IL-1, IFN-G, G-CSF and GM-CSF augment CFU-C activity in normal, cyclophosphamide-treated or irradiated mice as well as reduce the lethality of these myelotoxic agents 560
Protective, restorative, and therapeutic properties of recombinant colony-stimulating factors 541
Synthesis, structural properties, and pharmacological evaluation of 2-(acylamino)-thiophene-3-carboxamides and analogues thereof 540
Functional and surface phenotype study of lymphocyte subsets in peripheral blood and lymph nodes of breast cancer patients 538
Effects of Antiestrogen and Progestin on Immune Functions in Breast Cancer Patients 507
Regioselective synthesis of new EWG-Bearing 3-benzoyl-2-phenylbenzofurans by one-pot intramolecular acylation/thermal cyclization of phosphoranes and their CB1 antagonist activity 486
null 448
Correlations between Gustatory, Olfactory, Cognitive Function, and Age in Healthy Women 412
Dopamine D3 receptor antisense oligodeoxynucleotide potentiates imipramine-induced dopaminergic behavioural supersensitivity 292
null 281
Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination 256
Protective, restorative, and therapeutic properties of recombinant human IL-1 in rodent models. 218
Food restriction and hyperactivity induce changes in corticolimbic brain dopamine and serotonin levels in female rats 184
Correction to: Adolescent self‑administration of the synthetic cannabinoid receptor agonist JWH‑018 induces neurobiological and behavioral alterations in adult male mice 163
The novel synthesized naltrexone-related MOR antagonist AT-99 counteracts dopamine releasing and behavioral depressant morphine-induced effects 83
Totale 143.444
Categoria #
all - tutte 178.425
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 178.425


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.430 0 0 0 0 0 0 0 0 0 1.188 1.360 882
2021/20228.243 880 634 608 439 637 731 503 406 488 724 1.197 996
2022/202311.794 1.081 1.320 1.207 976 906 1.542 559 834 821 866 1.130 552
2023/202411.633 608 476 452 640 1.130 1.776 1.899 760 667 786 1.221 1.218
2024/202517.382 3.469 4.091 2.513 2.375 1.338 1.280 1.225 146 280 185 239 241
2025/20267.970 488 336 919 459 490 410 1.313 568 2.249 738 0 0
Totale 143.444